List view / Grid view
7 November 2011 | By Bristol-Myers Squibb Company
ERBITUX now approved for five indications across two tumor types...
7 November 2011 | By Abbott
In ABILITY-1 Study Presented at ACR, More than Twice as Many Patients Treated with HUMIRA Met Primary Endpoint Compared to Placebo...
5 November 2011 | By Merck
PROVIDE study results...
5 November 2011 | By Pfizer
PRESERVE trial results...
5 November 2011 | By
New long-term data show no development of resistance...
5 November 2011 | By Amgen
Positive data of the pivotal Phase 3 fracture trial...
5 November 2011 | By Abbott
PREMIER Eight-Year and DE019 10-Year Data Presented at ACR 2011...
3 November 2011 | By GlaxoSmithKline
$3 billion settlement covered by existing legal provisions...
3 November 2011 | By Bristol-Myers Squibb Company
Innovative strategic partnership to license and develop investigational oncology compound...
3 November 2011 | By Abbott
Abbott announced the company's schedule of key data presentations at the 23rd annual TCT scientific symposium...
3 November 2011 | By Renishaw
Raman spectroscopy came under the spotlight recently at the Natural History Museum in London...
2 November 2011 | By Eli Lilly and Company
John Lechleiter calls for balanced decision-making...
1 November 2011 | By College Hill
Sanofi is expected to take the top spot amongst the world’s pharmaceuticals manufacturers in 2012...
1 November 2011 | By Daiichi Sankyo
Daiichi Sankyo has established a new Japanese vaccine research unit to be located in its Kasai R&D Center...
Teva UK Limited has announced that Richard Daniell has been appointed as Managing Director, responsible for all Teva’s commercial activities in the UK.
